Details for Patent: 9,456,993
✉ Email this page to a colleague
Which drugs does patent 9,456,993 protect, and when does it expire?
Patent 9,456,993 protects XELSTRYM and is included in one NDA.
This patent has eighteen patent family members in ten countries.
Summary for Patent: 9,456,993
| Title: | Compositions and methods for transdermal delivery of amphetamine |
| Abstract: | Compositions for the transdermal delivery of amphetamine in a flexible, finite form are described. The compositions comprise a polymer matrix that includes amphetamine or a pharmaceutically acceptable salt or prodrug thereof and a backing layer comprising a polyurethane film layer and a polyester film layer, with a polyurethane adhesive disposed therebetween. Related methods also are described. Also described are compositions that exhibit a short onset period and a long duration of therapeutic effect. |
| Inventor(s): | Lambert; Robert L. (Miami, FL) |
| Assignee: | NOVEN PHARMACEUTICALS, INC. (Miami, FL) |
| Application Number: | 14/585,964 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Delivery; |
Drugs Protected by US Patent 9,456,993
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Noven Pharms Inc | XELSTRYM | dextroamphetamine | SYSTEM;TRANSDERMAL | 215401-001 | Mar 22, 2022 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | A METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER BY ADMINISTERING A TRANSDERMAL COMPOSITION CONTAINING AMPHETAMINE | ⤷ Subscribe | |||
| Noven Pharms Inc | XELSTRYM | dextroamphetamine | SYSTEM;TRANSDERMAL | 215401-002 | Mar 22, 2022 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | A METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER BY ADMINISTERING A TRANSDERMAL COMPOSITION CONTAINING AMPHETAMINE | ⤷ Subscribe | |||
| Noven Pharms Inc | XELSTRYM | dextroamphetamine | SYSTEM;TRANSDERMAL | 215401-003 | Mar 22, 2022 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | A METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER BY ADMINISTERING A TRANSDERMAL COMPOSITION CONTAINING AMPHETAMINE | ⤷ Subscribe | |||
| Noven Pharms Inc | XELSTRYM | dextroamphetamine | SYSTEM;TRANSDERMAL | 215401-004 | Mar 22, 2022 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | A METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER BY ADMINISTERING A TRANSDERMAL COMPOSITION CONTAINING AMPHETAMINE | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,456,993
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 093118 | ⤷ Subscribe | |||
| Argentina | 098878 | ⤷ Subscribe | |||
| Australia | 2014370133 | ⤷ Subscribe | |||
| Canada | 2889452 | ⤷ Subscribe | |||
| Canada | 2934924 | ⤷ Subscribe | |||
| European Patent Office | 2934496 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
